2019
DOI: 10.13005/bpj/1769
|View full text |Cite
|
Sign up to set email alerts
|

CD133 and CD166 as stem cell markers for predicting the possibility of developing prostatic cancer in cases of benign prostatic hyperplasia

Abstract: Benign and malignant prostatic diseases are generally well-known in the world. Accordingly, this research is planned to assess the immunohistochemical analysis of CD133 and CD166 in the prostatic epithelium in samples of benign prostatic hyperplasia (BPH) and normal looking epithelium around prostatic adenocarcinoma samples (PCa) and to explore the opportunity of malignant alterations in benign tissue. The prostate samples were divided into 2 groups; 50 BPH samples, and 50 normally looking tissue surrounding p… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

1
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 64 publications
1
1
0
Order By: Relevance
“…Recently, contradictory information about the accuracy of employing CD133 as a marker for CSCs identification and/or isolation has emerged (Glumac and Lebeau, 2018). Our findings showed that malignant cases had a significantly higher percentage and H-score of CD133 expression than the benign cases, agreeing with the findings of O'Brien et al, (2007) and Noel et al, (2019) which also showed that CD133 expression is lower in benign tissues than malignant tissue.…”
Section: Gc Ranks Fourth Among Cancer-related Fatalitiessupporting
confidence: 88%
“…Recently, contradictory information about the accuracy of employing CD133 as a marker for CSCs identification and/or isolation has emerged (Glumac and Lebeau, 2018). Our findings showed that malignant cases had a significantly higher percentage and H-score of CD133 expression than the benign cases, agreeing with the findings of O'Brien et al, (2007) and Noel et al, (2019) which also showed that CD133 expression is lower in benign tissues than malignant tissue.…”
Section: Gc Ranks Fourth Among Cancer-related Fatalitiessupporting
confidence: 88%
“…At low concentrations, IL-10 exerts an antitumor effect by different mechanisms, such as activating natural killer cells (NK), lymphocytes T, macrophages, and nitric oxide. In contrast, IL-10 manifests immune system deregulation at high concentrations, which allows the tumor to escape from immune recognition [22], [23]. Therefore, the expected mechanism of exHsp70 action with immune cells in CRC patients is explained in Fig.…”
Section: Discussionmentioning
confidence: 99%